Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers

An Open-label, Randomized, Response-adaptive Crossover Study to Investigate the Comparative Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers

1. Comparative evaluation of the safety of the drug Aterixen 100 mg tablets (Valenta Pharm JSC, Russia) and Aterixen 100 mg film-coated tablets (Valenta Pharm JSC, Russia) administered in single doses under fasting conditions in healthy volunteers, based on AE/SAE (adverse events/serious adverse event) analysis;
2. Comparative assessment of pharmacokinetic parameters and bioavailability of Aterixen 100 mg tablets (Valenta Pharm JSC, Russia) and Aterixen 100 mg film-coated tablets (Valenta Pharm JSC, Russia) administered in single doses under fasting conditions in healthy volunteers.
3. To conclude on the bioequivalence of Aterixen 100 mg tablets (Valenta Pharm JSC, Russia) and Aterixen 100 mg film-coated tablets (Valenta Pharm JSC, Russia) administered in single doses under fasting conditions in healthy volunteers.

Study Overview

• Status: Not yet recruiting
• Conditions: Viral Infection COVID-19
• Intervention / Treatment: Drug: Aterixen

• Study Type: Interventional
• Enrollment (Estimated): 36
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Russian Federation
  • Saint Petersburg,, Russian Federation, 196143
    • Limited Liability Company "Research Center Eco-Safety"
    • Contact: Vasiliy Vasilyuk, MD, PhD; Phone Number: +7 (901) 304 4248; Email: vasilyuk_vb@ecosafety.ru

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Voluntary and handwritten informed consent form signed by a healthy volunteer to participate in the study prior to any of the study procedures;
2. Healthy male and female caucasian volunteers aged 18 to 45 years (inclusive);
3. Verified diagnosis "healthy" (without abnormal findings in the protocol-defined clinical, laboratory, and instrumental test data);
4. Blood pressure (BP) levels: 99 to 129 mm Hg, inclusive (systolic, SBP), 70 to 89 mm Hg, inclusive (diastolic, DBP);
5. Heart rate (HR) of 60 to 89 bpm, inclusive;
6. Respiratory rate (RR) of 12 to 20 breaths per minute, inclusive;
7. Body temperature of 36°C to 36.9°C, inclusive;
8. Body mass index (BMI) of 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2, where the body weight range is ≥ 55 kg for men and ≥ 45 kg for women;
9. Consent to use adequate methods of contraception throughout the study and for 30 days after completion; for women of preserved reproductive potential, a negative urine pregnancy test result.

Exclusion Criteria:

1. A history of allergy;
2. Drug intolerance to the active substance N1-[2-(1-Methyl imidazol-4-yl)-ethyl]perhydroazin-2,6-dione (the active ingredient of Aterixen) and/or excipients contained in the studied drug in the anamnesis;
3. History of drug intolerance of N1-[2-(1-Methyl imidazol-4-yl)-ethyl]perhydroazin-2,6-dione (the active ingredient of Aterixen) aand/or excipients contained in the studied drug in the anamnesis;
4. History of hereditary galactose intolerance, lactase or glucose-galactose malabsorption
5. Chronic diseases of the kidneys, liver, gastrointestinal tract (GIT); disease of the circulatory, lymphatic, respiratory, nervous, endocrine, musculoskeletal, urogenital and the immune systems; dermal, hematopoietic, and ophthalmological diseases;
6. History of gastrointestinal surgery (except appendectomy at least 1 year prior to screening);
7. Diseases/conditions that, in the opinion of the investigator, may affect absorption, distribution, metabolism or excretion of the investigational drugs;
8. Acute infectious disease less than 4 weeks prior to screening;
9. Taking medications that significantly affect hemodynamics and medications that affect liver function (barbiturates, omeprazole, cimetidine, etc.) less than 2 months prior to screening;
10. Regularly taking an medicine less than 2 weeks before screening and taking a single medicine less than 7 days before screening (including OTC medicinal products, vitamins, dietary supplements, or medicinal herbs);
11. Donating blood or plasma less than 3 months before screening;
12. Use of hormonal contraceptives (in women) less than 2 months before screening;
13. The use of depot injections of any drug less than 3 months before screening;
14. Pregnancy or lactation; positive urine pregnancy test for women of preserved reproductive potential;
15. Women of preserved reproductive potential with a history of unprotected intercourse within 30 days prior to study drug administration with an unsterilized partner;
16. Participation in another clinical trial less than 3 months prior to screening or concurrently with the present study;
17. Taking more than 10 units of alcohol (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of wine or 50 ml of spirits) a week within a month prior to the enrollment in the study or history data of alcohol/drug dependence or drug abuse;
18. Smoking more than 10 cigarettes per day currently, or a history of smoking the specified number of cigarettes during the 6 months prior to screening; disagreement to abstain from smoking for the duration of the hospital stay;
19. Consumption of alcohol, caffeine, and xanthine-containing products 7 days prior to the study drug admission;
20. Consumption of citrus fruits, cranberries and products containing them, preparations or products containing St. John's wort - 7 days before admission to the study drug;
21. Dehydration due to diarrhea, vomiting, or other reason within the last 24 hours prior to study drug administration;
22. Positive blood tests for antibodies to human immunodeficiency virus (HIV) 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens at screening;
23. Positive rapid test for Coronavirus disease 2019 virus (COVID-19) at screening;
24. Clinically significant abnormalities on an electrocardiogram (ECG) history and/or at screening;
25. Positive urinalysis for narcotics and powerful drugs at screening;
26. Positive breath alcohol vapor test at screening.
27. Scheduling an inpatient stay at the time of the study, for any reason other than hospitalization required by this protocol;
28. Inability or inability to meet the requirements of the protocol, perform the procedures prescribed by the protocol, follow the diet, activity regimen.
29. Belonging to a vulnerable group of volunteers: students of higher and secondary medical, pharmaceutical and dental schools, junior staff of clinics and laboratories, employees of pharmaceutical companies, servicemen and prisoners, persons in nursing homes, low-income and unemployed, national minorities, homeless people, vagrants, refugees, persons under guardianship or custody, and persons unable to give consent, and law enforcement officers;
30. Other conditions that, in the opinion of the Researcher, prevent the inclusion of the volunteer in the study or that might lead to early withdrawal of the volunteer from the study, including fasting or a special diet (e.g. vegetarian, vegan, restricted salt intake) or a special lifestyle (night work, extreme physical activity).

Withdrawal Criteria:

1. The volunteer's refusal to further participate in the study;
2. Failure of the volunteer to comply with the rules of participation in the study (skipping study procedures, independent use of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.);
3. Occurrence of causes/occurrence during the study of situations that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.);
4. Volunteers selected for the study in violation of the inclusion/inclusion criteria;
5. Development of severe adverse event in the volunteer during the study;
6. The volunteer is undergoing or requires treatment that may affect the pharmacokinetic parameters;
7. Missing 2 or more consecutive blood samples or 3 or more blood samples during the same Study Period;
8. Occurrence of vomiting/diarrhea within 4 hours of study drug administration;
9. Positive urine test for narcotics and powerful drugs;
10. Positive breath alcohol vapor test.
11. Positive pregnancy test in women;
12. Positive test for COVID-19;
13. The occurrence in the course of the study of other reasons that prevent the study according to the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Experimental: RT-sequence; Group 1 (18 volunteers, RT sequence) will take 1 tablet of Aterixen,100 mg as a single dose in the fasting state in Period 1 and 1 tablet of Aterixen,100 mg film-coated tablet as a single dose in the fasting conditions in Period 2	Drug: Aterixen; A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Other: Experimental: TR-sequence; Group 2 (18 volunteers, TR sequence) will take 1 tablet of Aterixen,100 mg film-coated tablet as a single dose in the fasting state in Period 1 and 1 tablet of Aterixen,100 mg as a single dose in the fasting conditions in Period 2	Drug: Aterixen; A single dose of R or T drug in each of 2 periods of the study in fasted conditions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics - Cmax	Maximum plasma concentration (Cmax)	From 0 to 12 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - tmax	Time to reach Cmax (tmax)	From 0 to 12 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - AUC0-t	Area under the plasma concentration-time curve from time 0 to t (AUC0-t)	From 0 to 12 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - AUC0-inf	Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)	From 0 to 12 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - AUCextr	Extrapolated AUC, area under the concentration-time pharmacokinetic curve, to be calculated as Clast/Kel	From 0 to 12 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - t1/2	Elimination half-life (t1/2)	From 0 to 12 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - Kel	Elimination constant (Kel)	From 0 to 12 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - number of points in terminal logarithmic phase	Used to estimate Kel	From 0 to 12 hours (Day 1-2 and Day 8-9)
Bioequivalence - ratio of Cmax	Ratio of geometric mean Cmax after intake of R or T (with 90% confidence intervals)	From 0 to 12 hours (Day 1-2 and Day 8-9)
Bioequivalence - ratio of AUC0-t	Ratio of geometric mean AUC0-t after intake of R or T (with 90% confidence intervals)	From 0 to 12 hours (Day 1-2 and Day 8-9)
Bioequivalence - ratio of AUC0-inf	Ratio of geometric mean AUC0-inf after intake of R or T (with 90% confidence intervals)	From 0 to 12 hours (Day 1-2 and Day 8-9)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Tolerability: adverse event (AE) number and frequency	Number and frequency of adverse events (AEs) or serious AEs (SAEs)	From the screening (and signing informed consent form) to Day 14 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: adverse event (AE) characteristics	Description and severity of AEs or serious AEs (SAEs), concomitant therapy for AEs/SAEs, causal relationship, outcomes.	From the screening (and signing informed consent form) to Day 14 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - systolic blood pressure (SBP)	SBP, mmHg	Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - diastolic blood pressure (DBP)	DBP, mmHg	Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - respiratory rate (RR)	RR, breaths per minute	Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - heart rate (HR)	HR, beats per minute	Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - body temperature	Body temperature, centigrade scale	Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)	12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - color	Color of the urine	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - transparency	Transparency of the urine	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - pH	pH of the urine	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - specific gravity	Specific gravity of the urine	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - protein	Protein in the urine (g/L)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - glucose	Glucose in the urine (mmol/L)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - red blood cells	Red blood cells in the urine (number in sight)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - white blood cells	White blood cells in the urine (number in sight)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - epithelial cells	Epithelial cells in the urine (number in sight)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - cylinders	Cylinders in the urine (number in sight)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - mucus	Mucus in the urine (presence in sight)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - bacteria	Bacteria in the urine (number in sight)	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - hemoglobin	Hemoglobin, g/dL	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - red blood cells	Red blood cells, 10^6/uL	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - hematocrit	Hematocrit, %	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - platelets	Platelets, 10^3/uL	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - white blood cells	White blood cells, 10^3/uL	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - erythrocyte sedimentation rate	Erythrocyte sedimentation rate, mm per hour	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - neutrophils	Neutrophils, %	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - lymphocytes	Lymphocytes, %	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - eosinophils	Eosinophils, %	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - monocytes	Monocytes, %	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - basophils	Basophils, %	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - total protein	Total protein in blood serum, g/L	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - creatinine	Creatinine in blood serum, umol/L	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - glucose	Glucose in blood serum, mmol/L	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - total bilirubin	Total bilirubin in blood serum, umol/L	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - total cholesterol	Total cholesterol in blood serum, mmol/L	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - alanine transaminase (ALT)	ALT in blood serum, U/L	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - aspartate transaminase (AST)	AST in blood serum, U/L	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - alkaline phosphatase (ALP)	ALP in blood serum, U/L	Screening, Day 2, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: physical examination results	Number of participants with abnormal physical examination results	Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)

Collaborators and Investigators

• Sponsor: Valenta Pharm JSC

Study record dates

Study Major Dates

• Study Start (Estimated): June 15, 2024
• Primary Completion (Estimated): December 15, 2024
• Study Completion (Estimated): December 30, 2024

Study Registration Dates

• First Submitted: October 13, 2023
• First Submitted That Met QC Criteria: October 20, 2023
• First Posted (Actual): October 24, 2023

Study Record Updates

• Last Update Posted (Actual): March 29, 2024
• Last Update Submitted That Met QC Criteria: March 28, 2024
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Virus Diseases
• Other Study ID Numbers: ХС221-05-05-2022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No